At the news
? NEUTRALIMPACT 4/10 6-K filed Aug 20, 2026 at 07:36 ET
BioNTech filed a 6-K press release announcing upcoming data presentations at the IASLC 2026 World Conference on Lung Cancer (WCLC), including first global data for the novel-novel combination of pumitamig plus elfetabart drozuntecan and updated overall survival data for gotistobart from the PRESERVE-003 Phase 3 trial. The filing is a routine pipeline update with no financial data, and the actual clinical results will not be disclosed until the conference in September 2026, limiting near-term trading impact.
- BioNTech will present data at WCLC 2026 (Sept 12-15) from its lung cancer pipeline, including first data for pumitamig + elfetabart drozuntecan combination and updated OS for gotistobart.
- The filing is a curtain-raiser press release with no clinical results disclosed; actual data will be presented at the conference.
- BioNTech has 16 ongoing lung cancer trials, including five Phase 3 and two novel-novel combination trials.
- No financial figures, guidance, or material agreements were included in this filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access